Gardner Center for Parkinson's Disease

and Movement Disorders

234 Goodman Street, Cincinnati, Ohio 45219 | (866) 941-UCNI (8264)

Safety of Urate Elevation in Parkinson's Disease

Study Number: 
SURE-PD
Topic: 
Newly Diagnosed Parkinson's Disease
Pricipal Investigator: 
Alberto J Espay
Ongoing: 
Ongoing
Place: 
Medical Arts Building
Overview: 

To assess the safety of inosine in early PD, and to determine an optimal study design for a subsequent phase III RCT of inosine as a potential neuroprotective/disease-modifying therapy.

Specifically to: Assess in the short-term (12 wk) the tolerability of oral inosine and its capacity to elevate serum urate or CSF urate, at doses that should elevate serum urate from lower (< 5.5 mg/dL) levels to mildly (6.1 - 7.0 mg/dL) or moderately higher (7.1 - 8.0 mg/dL) levels.
 
Assess in the long-term (2 yr) whether oral inosine (at the dose selected as optimal after 12 wk) is tolerable and safe. Assess for any short-term symptomatic (anti-parkinsonian) effect.

Qualifications: 

Fulfillment of diagnostic criteria for idiopathic PD with at least two of the cardinal signs of PD (resting tremor, bradykinesia, rigidity), absence of current or imminent (within 3 months of enrollment) PD disability requiring dopaminergic therapy, H&Y 1.0-2.5 inclusive, Age >30 years, Diagnosis of PD made within 3 years of initial screening, and serum urate <5.5 mg/dL at initial screening.

Contact: 

For more information, please contact Maureen Gartner, RN, M.Ed. at maureen.gartner@uc.edu or (513) 558-0018.